Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
NCT03509896 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 463
Last updated 2022-06-27
Summary
Observational medical record review of newly diagnosed CML-CP participants in China
Conditions
- Chronic Myeloid Leukemia
- Philadelphia Chromosome
- Chronic Myeloid Leukemia in Chronic Phase
Interventions
- OTHER
-
Non-Interventional
Non-Interventional
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-11-30
- Primary Completion
- 2019-06-07
- Completion
- 2019-09-28
Countries
- China
Study Locations
More Related Trials
-
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
NCT00103701 ·Status: COMPLETED ·Phase: PHASE1
-
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
NCT00123487 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)
NCT00237120 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
NCT05413018 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients
NCT04933526 ·Status: UNKNOWN ·Phase: PHASE4
-
Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421
NCT01035307 ·Status: COMPLETED
-
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
NCT00574873 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
NCT05347225 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
NCT01660906 ·Status: COMPLETED ·Phase: PHASE4
-
Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib
NCT02348957 ·Status: COMPLETED
-
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
NCT00103844 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL
NCT05931757 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib
NCT04681820 ·Status: UNKNOWN
-
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan
NCT00337454 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Feasibility Pilot Exploring Variability in Biomarkers and PROs in AML
NCT04908852 ·Status: COMPLETED
-
Nilotinib for First-line Newly Diagnosed CML-CP Patients
NCT03942094 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial
NCT01004640 ·Status: UNKNOWN
-
A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
NCT00298987 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia
NCT01982175 ·Status: SUSPENDED ·Phase: PHASE2
-
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
NCT00129740 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
NCT01043874 ·Status: COMPLETED ·Phase: PHASE4
-
PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy
NCT00335868 ·Status: UNKNOWN ·Phase: PHASE2
-
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)
NCT00875693 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT05687032 ·Status: COMPLETED ·Phase: PHASE4